The Institute for Tuberculosis Research (ITR), located at the University of Illinois Chicago, is a drug discovery research facility working on the development of new drugs to combat an old, but still evolving global public health threat. The ITR is unique in that it brings an industrial model of drug discovery into an academic environment. In Chicago we have assembled all the necessary disciplines – microbiology, medicinal chemistry, natural products chemistry, structural biology, biochemistry, drug metabolism and pharmacokinetics– under one roof to maximize efficiency and communication. In addition to in-house discovery projects, we also collaborate with many public and private sector institutions around the world to facilitate their efforts towards the same goal.

Located in Chicago, our members come from 12 different countries. Our group includes 3 full-time and 2 part-time primary faculty, 6 affiliate faculty from the Department of Pharmaceutical Sciences, 4 adjunct faculty, 3 postdocs, 3 technicians and a business manager. We occupy 6300 sq. ft. of labs and offices in the College of Pharmacy.

Our research is supported by the Global Alliance for TB Drug Development, the National Institutes of Health, , fee-for-service arrangements from industry, and a patent royalty stream. Our annual budget consists of over 2.5 million dollars.